Prevalence of obstructive sleep apnea in patients with retinal vein occlusion
Mon statut pour la session
Quoi:
Paper Presentation | Présentation d'article
Quand:
4:10 PM, Dimanche 3 Juin 2018
(10 minutes)
Où:
Metro Toronto Convention Centre (Édifice Sud)
- Salle 803
Authors: Michael H. Brent, Tina Felfeli, Efrem D. Mandelcorn, Colin Shapiro, Roy Alon
Author Disclosure Block: M. Brent: Grant/research support; Novartis, Allergan, Bayer, Roche. Membership on an advisory panel, standing committee or board of directors; Novartis, Bayer, Allergan, Alcon. T. Felfeli: None. E. Mandelcorn: Employment/honoraria/consulting fees; Novartis, Bayer, Optos, Bausch & Lomb. C. Shapiro: None. R. Alon: None.
Abstract Body:
Purpose: Retinal Vein Occlusion (RVO) is one of the most common sight threatening retinal vascular disorders. Recent publications have suggested an association between Obstructive Sleep Apnea (OSA) and retinal vein occlusion. It is commonly known that patients with RVO exhibit symptoms of visual loss upon awakening, which alludes to the possibility that nocturnal events contribute to its pathogenesis. The purpose of this study is to investigate the prevalence of OSA in patients with RVO, in the Retina Service at the Donald K Johnson Eye Institute at the University Health Network, Toronto.
Study Design: Prospective cross sectional study.
Methods: Research Ethics Board (REB) approval has been granted. Patients with RVO, diagnosed clinically, and confirmed with intravenous fluorescein angiography, will be recruited. The patients will have to answer two standard questionnaires used to screen for OSA (Berlin questionnaire+ STOP BANG questionnaire), their answers will be scored and recorded, and all patients will be sent for a sleep test at a certified sleep lab. The prevalence of OSA in RVO patients will be calculated, and the ability of each questionnaire to accurately detect OSA will be determined. A sub group analysis will be performed to assess for possible differences between patients with central retinal vein occlusion vs. branch retinal vein occlusion. Patients with positive results for OSA, will be offered the appropriate treatment with a sleep apnea specialist.
Results: 27 patients have been enrolled in the study to date (14 with CRVO/HRVO and 13 with BRVO). All patients enrolled in the study completed the two questionnaires. Of 14 patients that have completed their sleep test, three were found to have severe OSA, eight had moderate OSA, and three patients had mild OSA. According to our current findings, the prevalence of OSA in RVO patients is 100%. Our findings showed that the STOP BANG questionnaire has a sensitivity of 79%, and the Berlin questionnaire has a sensitivity of 43% for detecting OSA. Of the 14 patients who have had a sleep test, eight have subsequently been treated for OSA with Continuous positive air pressure machine (CPAP) and six are scheduled for a sleep specialist assessment.
Conclusions: Based on the results to date, the prevalence of OSA in RVO patients appears to be high.
Author Disclosure Block: M. Brent: Grant/research support; Novartis, Allergan, Bayer, Roche. Membership on an advisory panel, standing committee or board of directors; Novartis, Bayer, Allergan, Alcon. T. Felfeli: None. E. Mandelcorn: Employment/honoraria/consulting fees; Novartis, Bayer, Optos, Bausch & Lomb. C. Shapiro: None. R. Alon: None.
Abstract Body:
Purpose: Retinal Vein Occlusion (RVO) is one of the most common sight threatening retinal vascular disorders. Recent publications have suggested an association between Obstructive Sleep Apnea (OSA) and retinal vein occlusion. It is commonly known that patients with RVO exhibit symptoms of visual loss upon awakening, which alludes to the possibility that nocturnal events contribute to its pathogenesis. The purpose of this study is to investigate the prevalence of OSA in patients with RVO, in the Retina Service at the Donald K Johnson Eye Institute at the University Health Network, Toronto.
Study Design: Prospective cross sectional study.
Methods: Research Ethics Board (REB) approval has been granted. Patients with RVO, diagnosed clinically, and confirmed with intravenous fluorescein angiography, will be recruited. The patients will have to answer two standard questionnaires used to screen for OSA (Berlin questionnaire+ STOP BANG questionnaire), their answers will be scored and recorded, and all patients will be sent for a sleep test at a certified sleep lab. The prevalence of OSA in RVO patients will be calculated, and the ability of each questionnaire to accurately detect OSA will be determined. A sub group analysis will be performed to assess for possible differences between patients with central retinal vein occlusion vs. branch retinal vein occlusion. Patients with positive results for OSA, will be offered the appropriate treatment with a sleep apnea specialist.
Results: 27 patients have been enrolled in the study to date (14 with CRVO/HRVO and 13 with BRVO). All patients enrolled in the study completed the two questionnaires. Of 14 patients that have completed their sleep test, three were found to have severe OSA, eight had moderate OSA, and three patients had mild OSA. According to our current findings, the prevalence of OSA in RVO patients is 100%. Our findings showed that the STOP BANG questionnaire has a sensitivity of 79%, and the Berlin questionnaire has a sensitivity of 43% for detecting OSA. Of the 14 patients who have had a sleep test, eight have subsequently been treated for OSA with Continuous positive air pressure machine (CPAP) and six are scheduled for a sleep specialist assessment.
Conclusions: Based on the results to date, the prevalence of OSA in RVO patients appears to be high.
